Related references
Note: Only part of the references are listed.The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naive patients with idiopathic cervical dystonia
Harald Hefter et al.
JOURNAL OF NEUROLOGY (2021)
The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
Sara Samadzadeh et al.
TOXINS (2021)
Botulinum toxin therapy of dystonia
Dirk Dressler et al.
JOURNAL OF NEURAL TRANSMISSION (2021)
Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
Steven Bellows et al.
TOXINS (2020)
Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
Sara Samadzadeh et al.
TOXINS (2020)
Botulinurn toxin type A therapy for cervical dystonia
Filipe B. Rodrigues et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
Harald Hefter et al.
FRONTIERS IN NEUROLOGY (2020)
Remission in dystonia Systematic review of the literature and meta-analysis
Tina Mainka et al.
PARKINSONISM & RELATED DISORDERS (2019)
Immunogenicity Associated with Botulinum Toxin Treatment
Steven Bellows et al.
TOXINS (2019)
High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy
Philipp Albrecht et al.
NEUROLOGY (2019)
Update on current and emerging therapies for dystonia
Karlo J. Lizarraga et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2019)
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?
H. A. Jinnah et al.
TOXICON (2018)
Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study
Marek Moll et al.
PARKINSONISM & RELATED DISORDERS (2018)
Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment
Sanjay Pandey et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Clinical Practice: evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin
Maria Fiorella Contarino et al.
FRONTIERS IN NEUROLOGY (2017)
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes
H. A. Jinnah et al.
JOURNAL OF NEUROLOGY (2016)
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M. Simpson et al.
NEUROLOGY (2016)
High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment
Harald Hefter et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2016)
Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial
Jens Volkmann et al.
LANCET NEUROLOGY (2014)
Phenomenology and classification of dystonia: A consensus update
Alberto Albanese et al.
MOVEMENT DISORDERS (2013)
Botulinum toxin therapy for spasmodic torticollis. Medical and non-medical adjunct treatment
B. Leplow et al.
NERVENARZT (2013)
An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)
H. Hefter et al.
BMJ OPEN (2013)
Continuation of Long-Term Care for Cervical Dystonia at an Academic Movement Disorders Clinic
Chandler E. Gill et al.
TOXINS (2013)
The Prevalence of Primary Dystonia: A Systematic Review and Meta-analysis
Thomas D. Steeves et al.
MOVEMENT DISORDERS (2012)
CT-guided intramuscular botulinum toxin A injections into the deep anterior neck muscles in patients with pure antecaput or antecollis
H. Hefter et al.
BASAL GANGLIA (2012)
Factors predicting protracted improvement after pallidal DBS for primary dystonia: the role of age and disease duration
Ioannis U. Isaias et al.
JOURNAL OF NEUROLOGY (2011)
Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia
Kapil D. Sethi et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients
Fernanda Martins Maia et al.
PARKINSONISM & RELATED DISORDERS (2010)
Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?
Oliver Lange et al.
CLINICAL NEUROPHARMACOLOGY (2009)
'Why do children with cerebral palsy discontinue therapy with botulinum toxin A?'
M Linder-Lucht et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2006)
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R Benecke et al.
NEUROLOGY (2005)
Long-term botulinum toxin efficacy, safety, and immunogenicity
NI Mejia et al.
MOVEMENT DISORDERS (2005)
The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment
IM Skogseid et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Long-term follow-up of cervical dystonia patients treated with botulinum toxin A
P Haussermann et al.
MOVEMENT DISORDERS (2004)
Clinical presentation and management of antibody-induced failure of botulinum toxin therapy
D Dressler
MOVEMENT DISORDERS (2004)
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period
GYR Hsiung et al.
MOVEMENT DISORDERS (2002)
Share Paper
